DUODOPA GEL

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

CARBIDOPA (CARBIDOPA MONOHYDRATE); LEVODOPA

Saatavilla:

ABBVIE CORPORATION

ATC-koodi:

N04BA02

INN (Kansainvälinen yleisnimi):

LEVODOPA AND DECARBOXYLASE INHIBITOR

Annos:

5MG; 20MG

Lääkemuoto:

GEL

Koostumus:

CARBIDOPA (CARBIDOPA MONOHYDRATE) 5MG; LEVODOPA 20MG

Antoreitti:

INTRAINTESTINAL (UPPER)

Kpl paketissa:

7 CASSETTES (100G/EA)

Prescription tyyppi:

Prescription

Terapeuttinen alue:

DOPAMINE PRECURSORS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0210315005; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2007-03-01

Valmisteyhteenveto

_DUODOPA (levodopa/carbidopa) _
_Date of Revision: April 4, 2022 _
_Submission Control No.: 252247 _
_Page 1 of 54 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
DUODOPA®
levodopa/carbidopa intestinal gel
20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate
Antiparkinson Agent (ATC Code: N04BA02
)
DUODOPA (LEVODOPA/CARBIDOPA INTESTINAL GEL) TREATMENT SHOULD BE
INITIATED AND SUPERVISED ONLY BY
NEUROLOGISTS AND SPECIALIZED HEALTHCARE PROFESSIONALS EXPERIENCED AND
TRAINED IN THE DIAGNOSIS AND
TREATMENT OF PATIENTS WITH PARKINSON’S DISEASE, WHO HAVE COMPLETED
THE DUODOPA EDUCATION
PROGRAM AND ARE FAMILIAR WITH THE DUODOPA EFFICACY AND SAFETY PROFILE.
®Trademark of AbbVie AB; Licensed use by AbbVie Corporation,
Saint-Laurent, QC, H4S 1Z1.
AbbVie Corporation
8401 Trans-Canada Highway
St-Laurent, QC H4S 1Z1
Date of Initial Authorization:
FEB 20, 2007
Date of Revision:
April 4, 2022
Submission Control Number: 252247
_DUODOPA (levodopa/carbidopa) _
_Date of Revision: April 4, 2022 _
_Submission Control No.: 252247 _
_Page 2 of 54 _
RECENT MAJOR LABEL CHANGES
7 Warnings and Precautions
02/2020
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................